We agree that meta-analyses can provide useful information in assessing the risk of adverse events, particularly that of uncommon adverse events. Previous meta-analyses have been limited by the hetero geneity of study populations and clinical trial protocols, variations in t estosterone regimens and on-treatment testosterone levels, relatively small sample sizes, and poor ascertain ment of adverse events in clinical trials. The updated metaanalysis by Xu et al. 3 includes several trials that were not included in prior analyses and thus provides a more precise estimate of the rate of cardio vascular events than previous meta-analyses. 4,5 Nevertheless, large, prospective, randomized controlled trials are important for the evaluation of testosterone's efficacy in improving patientimportant outcomes as well as for determining the risks of testosterone therapy and ascertaining whether some subsets of Schooling and Cowling suggest that large prospective randomized trials to establish the effects of testosterone on cardio vascular health should be of an agent that reduces testosterone. This proposal has considerable merit, but we do not think that statins are the right drugs for this purpose, as they exert only a modest effect on testosterone levels and are well-known to reduce LDLcholesterol levels, which has an independent effect on cardiovascular events. As indicated by the authors, statins lower serum testosterone levels by 0.66 nmol/l in men.
CORRESPONDENCE
We much appreciate the thoughtful comments of Dr Schooling and Dr Cowling (Nat. Rev. Endocrinol. 9, doi:10.1038 / nrendo.2013 1 on our Review (Risks and benefits of testosterone therapy in older men. Nat. Rev. Endocrinol. 9, doi:10.1038 / nrendo.2013 . 2 We agree that meta-analyses can provide useful information in assessing the risk of adverse events, particularly that of uncommon adverse events. Previous meta-analyses have been limited by the hetero geneity of study populations and clinical trial protocols, variations in t estosterone regimens and on-treatment testosterone levels, relatively small sample sizes, and poor ascertain ment of adverse events in clinical trials. The updated metaanalysis by Xu et al.
3 includes several trials that were not included in prior analyses and thus provides a more precise estimate of the rate of cardio vascular events than previous meta-analyses. 4, 5 Nevertheless, large, prospective, randomized controlled trials are important for the evaluation of testosterone's efficacy in improving patientimportant outcomes as well as for determining the risks of testosterone therapy and ascertaining whether some subsets of Schooling and Cowling suggest that large prospective randomized trials to establish the effects of testosterone on cardio vascular health should be of an agent that reduces testosterone. This proposal has considerable merit, but we do not think that statins are the right drugs for this purpose, as they exert only a modest effect on testosterone levels and are well-known to reduce LDLcholesterol levels, which has an independent effect on cardiovascular events. As indicated by the authors, statins lower serum testosterone levels by 0.66 nmol/l in men.
6 Of note, men with prostate cancer undergoing androgen deprivation therapy exhibit profound suppression of testosterone levels and an increased risk of diabetes mellitus and cardiovascular disease. Hence, low as well as high testosterone levels might be a ssociated with an increased cardiovascular risk. Men's Health: Ageing and Metabolism, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA (M. Spitzer, G. Huang, S. Basaria, T. G. Travison, S. Bhasin) .
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